Medico Intercontinental Limited

ICLF

INE858Q01019

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 12:30:41 18/05/2024 pm IST			5-day change	1st Jan Change
47.8 ^INR	-0.19%		+8.27%	-48.57%

25/04	Medico Intercontinental Limited Announces Resignation of Nikul Dipakbhai Shah as Independent Director	CI
09/04	Medico Intercontinental Limited Proposes to Incorporate Joint Venture Partnership Firm	CI

Medico Intercontinental Limited Reports Earnings Results for the First Quarter Ended June 30, 2020

September 15, 2020 at 02:23 pm IST

Medico Intercontinental Limited announced earnings results for the first quarter ended June 30, 2020. For the first quarter, the company announced total revenue was INR 199.928 million compared to INR 182.554 million a year ago. Net income was INR 6.653 million compared to INR 5.858 million a year ago. Basic earnings per share was INR 2.05 compared to INR 1.8 a year ago.

Latest news about Medico Intercontinental Limited

Medico Intercontinental Limited Announces Resignation of Nikul Dipakbhai Shah as Independent Director	25/04	CI
Medico Intercontinental Limited Proposes to Incorporate Joint Venture Partnership Firm	09/04	CI
Medico Intercontinental Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14/02	CI
Medico Intercontinental Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	08/11	CI
Medico Intercontinental Limited Approves Final Equity Dividend for the Financial Year 2022-23	30/23/30	CI
Medico Intercontinental Limited Approves the Regularisation of Priyank Lalitbhai Sancheti as an Independent Director	30/23/30	CI
Medico Intercontinental Limited Reports Earnings Results for the Full Year Ended March 31, 2023	06/23/06	CI
Medico Intercontinental Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	29/23/29	CI
Medico Intercontinental Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable on or After July 5, 2023	29/23/29	CI
Medico Intercontinental Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/23/14	CI
Medico Intercontinental Limited Appoints Priyank L Sancheti as an Additional Independent Director	14/22/14	CI
Medico Intercontinental Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/22/14	CI
Medico Intercontinental Limited Approves Regularisation of Nikul Dipakbhai Shah as an Independent Director	28/22/28	CI
Medico Intercontinental Limited announced that it expects to receive INR 249.787 million in funding	27/22/27	CI
Medico Intercontinental Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	13/22/13	CI
Medico Intercontinental Limited Announces Resignation Mr. Hiren Ravindrabhai Shah as Independent Director	30/22/30	CI
Medico Intercontinental Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/22/14	CI
Medico Intercontinental Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	12/21/12	CI
Medico Intercontinental Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	14/21/14	CI
Medico Intercontinental Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	29/21/29	CI
Medico Intercontinental Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	12/21/12	CI
Medico Intercontinental Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	14/20/14	CI
Medico Intercontinental Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	15/20/15	CI
Medico Intercontinental Limited Appoints Hiren Ravindrabhai Shah as Independent Director	04/20/04	CI
Medico Intercontinental Limited Appoints Hiren Ravindrabhai Shah as an Additional Independent Director	04/20/04	CI

Chart Medico Intercontinental Limited

Duration

Period

More charts

Company Profile

Medico Intercontinental Ltd is engaged in the business of trading of pharmaceutical products. It provides platform to all research-based biopharmaceutical companies. Its product categories include gastro, uro, nutrition, cosmetology, health devices, hospital, and other areas. Its products include ACIFACT-BLI, ACIFACT-P, ACIFACT-SP (ALU-ALU), ALBECTIN, ALFACARE - D3, ARSUFACT Combokit, BALOFACT, CYCLOFACT 400, UDIFACT 150, XOFACT - 4, ZIFT SL - 250, ZYMIX, ARGIFACT, CLIANCIACT POWDER, RELIEVE CZ, VOLIREX SPRAY, RACIMAX SACHET, PERMACT, OROFACT, KTZ, FEMYACT, LIVOFACT, ZYMIX SY, ULTRATONE SY, ALBECTIN SUS, BECOFACT DROPS, MEFACT P SUS, ONCARE SOLUTION, OFCARE-FORTE SUS, PRODOM CV SY., RELIBEN SUSP., ZIFT SUSP.-200 MGCIPACT EYE DROP, OROFACT-PASTE(lamy), OROFACT MOUTH ULCER GEL, CALAMED LOTION and others. Its subsidiaries include Evagrace Pharma Private Limited, Ritz Formulations Private Limited, Sungrace Pharma Private Limited, and Azillian Healthcare Private Limited.

Sector

Pharmaceuticals

Calendar

27/05/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
MEDICO INTERCONTINENTAL LIMITED	-48.57%	5.75M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.63%	44.11B
OTSUKA HOLDINGS CO., LTD.	+23.03%	22.71B
SANDOZ GROUP AG	+18.22%	15.15B
CIPLA LIMITED	+12.66%	13.56B
ZYDUS LIFESCIENCES LIMITED	+60.18%	12.7B
ONO PHARMACEUTICAL CO., LTD.	-10.02%	6.84B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+12.92%	5.63B

Generic Pharmaceuticals